PCN248 ESTIMATING THE UNBIASED OS-BENEFIT FOR APALUTAMIDE (APA) VERSUS ANDROGEN DEPRIVATION THERAPY (ADT) IN PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) FROM SPARTAN, ADJUSTING FOR SUBSEQUENT THERAPY USING RAN ...
Abstract
Authors
J. Diels N. Perualila J. Sermon U. Siebert S. van Sanden